WO2012070068A2 - Process for preparation of triclabendazole - Google Patents
Process for preparation of triclabendazole Download PDFInfo
- Publication number
- WO2012070068A2 WO2012070068A2 PCT/IN2011/000810 IN2011000810W WO2012070068A2 WO 2012070068 A2 WO2012070068 A2 WO 2012070068A2 IN 2011000810 W IN2011000810 W IN 2011000810W WO 2012070068 A2 WO2012070068 A2 WO 2012070068A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dichlorophenoxy
- chloro
- triclabendazole
- triciabendazole
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Definitions
- the present invention relates to a novel, cost-effective process for preparation of Triclabendazole.
- Triclabendazole chemically known as 5-chloro-6-(2,3-dichlorophenoxy)-2- (methylthio)-lH-benzimidazole represented by formula I,
- the obtained diamine of formula III is cyclised in presence of carbondisulfide to obtain 6-chloro-5-(2,3-dichlorophenoxy)- lH-benzimidazole-2-thiol of formula II.
- the compound of formula II is methylated using dimethyl sulphate to obtain Triclabendazole of formula I.
- the process disclosed in this patent is illustrated in scheme 1 below:
- the principal aspect of the present invention is to provide a process for the preparation of Triclabendazole comprising:
- Triclabendazole hydrochloride of formula X hydrolysing Triclabendazole hydrochloride of formula X to obtain Triclabendazole of formula I.
- the condensation and hydrolysis in step a) and b) is carried out in-situ in presence of a polar aprotic solvent like dimethylformamide (DMF), DMSO, sulfolane ⁇ N-methylpyrrolidinone and alcoholic solvent like methanol at a temperature 30 °C to 100 °C preferably at 50 °C to 90 °C.
- the base used for the condensation and hydrolysis are sodium carbonate, potassium carbonate, or sodium hydroxide or potassium hydroxide.
- the condensation is preferably carried out in presence of solvent dimethylformamide and base potassium carbonate whereas the hydrolysis is done in presence of sodium hydroxide.
- no phase transfer catalyst is required for the condensation of the present invention.
- the reduction in step c) is carried out in an alcoholic solvent like methanol, ethanol, isopropanol, preferably in presence of methanol and Raney nickel and sodium hydroxide.
- an alcoholic solvent like methanol, ethanol, isopropanol, preferably in presence of methanol and Raney nickel and sodium hydroxide.
- the reduction is carried out at H 2 pressure of 6 kg and at temperature about 100 °C.
- the obtained 4-chloro-5(2,3-dichlorophenoxy)-l,2- phenylenediamine in step c is directly cyclized with carbon disulfide in presence of strong base such as caustic lye without isolating followed by acidification with acetic acid.
- the cyclisation or ring closure in step d) is carried out at a temperature 50 °C to 140 °C in presence of carbondisulfide, a solvent selected from dimethylformamide, methanol, ethanol, or acetonitrile, preferably methanol and in presence of a base like sodium hydroxide.
- methylation 6-chloro-5-(2,3- dichlorophenoxy)-lH-benzimidazole-2 -thiol of formula II in step e) is carried out using a methylating agent like dimethylsulfate in temperature range of 20 to 80 °C preferably 40 to 65 °C. and in presence of an alcoholic solvent preferably methanol to obtain Triclabendazole methanesulfonate salt.
- a methylating agent like dimethylsulfate in temperature range of 20 to 80 °C preferably 40 to 65 °C. and in presence of an alcoholic solvent preferably methanol to obtain Triclabendazole methanesulfonate salt.
- the obtained 4-chloro-5(2,3-dichlorophenoxy)-l ,2- phenylenediamine in step c is directly cyclized with carbon disulfide in presence of strong base such as caustic lye without isolating followed by acidification with acetic acid.
- Triclabendazole methanesulfonate salt is dissolved in an alcoholic solvent preferably methanol, charcolated and added concentrated hydrochloric acid and cooled to isolate hydrochloride salt of Triclabendazole. Which is further treated with water and ammonia to obtain Triclabendazole.
- 6-chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2 -thiol of formula II is methylated using a methylating agent like dimethylsulfate in presence of an alcoholic solvent preferably methanol and a base preferably sodium carbonate in temperature range of 40 to 90 °C preferably 60 to 90 °C. to obtain Triclabendazole directly.
- the obtained triclabendazole is optionally purified by dissolving in toluene at 90 -100 °C, removing water azeotropically, cooling & charcolyzing, and again adding isopropanol at 90 -100 °C.
- Raney nickel (10.8 g) was added into a reaction mixture containing 4-chIoro- 5(2,3-dichlorophenoxy)-2-nitroaniline (900 g), methanol (3.4 L) at RT, caustic lye (2.72 g). Nitrogen was flushed into and charged with hydrogen. The reaction mixture was heated slowly to 100°C for 12 hrs, cooled to RT and filtered.
- 6-chloro-5(2,3-dichlorophenoxy)-l H- benzimidazole-2-thiol(400kg) was added to methanol (700 L) and heated to 40°C. Dimethyl sulphate was added slowly at 40°C to it. The reaction mass was heated to 60-65°C and maintain for 6hrs. After completion of the reaction the reaction mass was cooled to 15°C, centrifuged the material and washed with 75 L of methanol to obtain wet cake of Triclabendazole methanesulfonate (520-560 kg).
- Triclabendazole methanesulfonate 200 g
- methanol 1.2 L
- Triclabendazole methanesulfonate 200 g
- charcoal cooled and charcoal was added and refluxed again for 1 hr.
- the reaction mass was filtered and concentrated hydrochloric acid was added.
- the precipitate was ' cooled to RT, stirred for 1 hr, filtered and Triclabendazole hydrochloride was isolated (250 g wet) .
- Triclabendazole hydrochloride The water was added to the above Triclabendazole hydrochloride and ammonia was charged and stired for 2-3 hrs. The reaction mass was filtered, washed with water and dried to obtain Triclabendazole.
- Example 2 Preparation of 6-chloro-5(2,3-dichlorophenoxy)-2-(metylthio)-lH- benzimidazole
- 6-chloro-5(2,3-dichlorophenoxy)-lH- benzimidazole-2-thiol (200 g) and dimethylsulfate (40 g) were heated to 60 ⁇ 2°C and water (100 mL) was added and stirred for half an hr.
- Sodium carbonate solution 25 g Na 2 CC>3 in 200 mL water
- the reaction mixture was cooled to 60°C, filtered, washed with water further washed with toluene and dried.
- Triclabendazole was heated to 90-100°C in toluene (1.92 litre). Water was removed azeotropically. The solution/mixture was cooled charcoal was added, refluxed and filtered. Again the obtained material was heated to 90-100°C, 180 ml of IPA was added, cooled to RT, filtered and dried for 24 hrs at 90-100°C.
Abstract
The present invention discloses a method for preparing Triclabendazole comprising condensing N-(4,5-dichloro-2-nitrophenyl)acetamide with 2,3-dichlorophenol to obtain 4-chloro-5(2,3-dichlorophenoxy)-2-nitrophenyl acetamide and it to obtain 4- chloro-5(2,3-dichlorophenoxy)-2-nitroaniline; reducing 4-chloro-5(2,3- dichlorophenoxy)-2-nitroaniline in presence of Raney nickel to obtain 4-chloro-5- (2,3-dichlorophenoxy)benzene-l,2-diamine of; cyclising 4-chloro-5-(2,3- dichlorophenoxy)benzene-l,2-diamine in presence of carbondisulfide to obtain 6- chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2-thiol; methylating 6-chloro-5- (2,3-dichlorophenoxy)-lH-benzimidazole-2 -thiol using a methylating agent to obtain triclabendazole methanesulfonate salt; converting triclabendazole methanesulfonate salt to hydrochloride salt of Triclabendazole and hydrolysing it to obtain Triclabendazole.
Description
Process for Preparation of Triclabendazole
Field of Invention
The present invention relates to a novel, cost-effective process for preparation of Triclabendazole.
Background of the Invention
Triclabendazole, chemically known as 5-chloro-6-(2,3-dichlorophenoxy)-2- (methylthio)-lH-benzimidazole represented by formula I,
is a halogenated benzimidazole compound that possesses high activity against immature and adult stages of the liver fluke, Faciola hepatica. The intensive use of Triclabendazole in endemic areas of facioliasis has resulted in the development of liver flukes resistant to this compound.
US 4, 197,307 discloses the process for the preparation of Triclabendazole, wherein 4- chloro-5-(2,3-dichlorophenoxy)-l,2-benzenediamine is reacted with carbondisulfide to give cyclic benzimidazole thione, which is further subjected to alkylation reaction with dimethyl sulfate to give Triclabendazole.
Chinese patent 10155523 ldescribes a process for the preparation of Triclabendazole by hydrolysing N-(4,5-dichloro-2-nitrophenyl)acetamide of formula VII to 4,5- dichloro-2-nitroaniline of formula VIII and condensing it with 2,3-dichlorophenol of formula VI in presence of a phase transfer catalyst to obtain 4-chloro-5(2,3- dichlorophenoxy)-2-nitroaniline of formula IV, which is further reduced in presence of Iron to obtain 4-chloro-5-(2,3-dichlorophenoxy)benzene-l ,2-diamine of formula III. The obtained diamine of formula III is cyclised in presence of carbondisulfide to obtain 6-chloro-5-(2,3-dichlorophenoxy)- lH-benzimidazole-2-thiol of formula II. The
compound of formula II is methylated using dimethyl sulphate to obtain Triclabendazole of formula I. The process disclosed in this patent is illustrated in scheme 1 below:
Scheme 1
6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazole-2-t ioi 4-chloro-5-(2,3-dichlorop enoxy)benzene-1 ,2-diamine
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
I
However, the above prior art process is not preferred at a commercial scale because the hydrolysis of N-(4,5-dichloro-2-nitrophenyl)acetamide of formula VII is carried out before condensation with 2,3-dichlorophenol of formula VI, which is labile to formation of impurities and moreover the condensation is carried out in the presence of a phase transfer catalyst. Further, Iron is used as a catalyst for reduction which is riot environment friendly and involves tedious work-up. The final compound Triclabendazole is directly obtained by the methylating the compound of formula II using dimethylsulfate. The purity of thus obtained Triclabendazole is not high.
Thus it is highly desirable to develop a process which overcomes most of the prior art drawbacks. The present inventors have developed a process for the preparation of Thiabendazole, which is environment friendly, technologically safe, simple and cost effective
Summary of the Invention
The principal aspect of the present invention is to provide a process for the preparation of Triclabendazole comprising:
a) condensing N-(4,5-dichloro-2-nitrophenyl)acetamide of formula VII with 2,3- dichlorophenol of formula VI to obtain 4-chloro-5(2,3-dichlorophenoxy)-2- nitrophenyl acetamide of formula V;
b) hydrolysing 4-chloro-5(2,3-dichlorophenoxy)-2-nitrophenyl acetamide of formula V to obtain 4-chloro-5(2,3-dichlorophenoxy)-2-nitroaniline of formula IV;
c) reducing 4-chloro-5(2,3-dichlorophenoxy)-2-nitroaniline of formula IV in presence of Raney nickel to obtain 4-chloro-5-(2,3-dichlorophenoxy)benzene- 1 ,2-diamine of formula III;
d) cyclising 4-chloro-5-(2J3-dichlorophenoxy)benzene-l ,2-diamine of formula III in presence of carbondisulfide to obtain 6-chloro-5-(2,3-dichlorophenoxy)-lH- benzimidazole-2-thiol of formula II;
e) methylating '6-chloro-5-(2,3-diehlorophenoxy)^lH-benzimidazole-2-thiol of formula II using a methylating agent to obtain Triclabendazole methanesulfonate salt of formula IX;
f) converting Triclabendazole methanesulfonate salt of formula . IX to hydrochloride salt of Triclabendazole of formula X; and
g) hydrolysing Triclabendazole hydrochloride of formula X to obtain Triclabendazole of formula I.
The process of the present invention is illustrated in scheme 2 below:
Scheme 2
+ NH4CI + H20
Detail Description of the Invention
Accordingly in an embodiment of the invention, the condensation and hydrolysis in step a) and b) is carried out in-situ in presence of a polar aprotic solvent like dimethylformamide (DMF), DMSO, sulfolane^ N-methylpyrrolidinone and alcoholic solvent like methanol at a temperature 30 °C to 100 °C preferably at 50 °C to 90 °C. The base used for the condensation and hydrolysis are sodium carbonate, potassium carbonate, or sodium hydroxide or potassium hydroxide. The condensation is preferably carried out in presence of solvent dimethylformamide and base potassium carbonate whereas the hydrolysis is done in presence of sodium hydroxide.
In further embodiment no phase transfer catalyst is required for the condensation of the present invention.
In another embodiment of the invention, the reduction in step c) is carried out in an alcoholic solvent like methanol, ethanol, isopropanol, preferably in presence of methanol and Raney nickel and sodium hydroxide. Preferably the reduction is carried out at H2 pressure of 6 kg and at temperature about 100 °C.
In another embodiment the obtained 4-chloro-5(2,3-dichlorophenoxy)-l,2- phenylenediamine in step c is directly cyclized with carbon disulfide in presence of strong base such as caustic lye without isolating followed by acidification with acetic acid.
In another embodiment of the invention, the cyclisation or ring closure in step d) is carried out at a temperature 50 °C to 140 °C in presence of carbondisulfide, a solvent selected from dimethylformamide, methanol, ethanol, or acetonitrile, preferably methanol and in presence of a base like sodium hydroxide.
In another embodiment of the invention, methylation 6-chloro-5-(2,3- dichlorophenoxy)-lH-benzimidazole-2 -thiol of formula II in step e) is carried out using a methylating agent like dimethylsulfate in temperature range of 20 to 80 °C preferably 40 to 65 °C. and in presence of an alcoholic solvent preferably methanol to obtain Triclabendazole methanesulfonate salt.
In another embodiment the obtained 4-chloro-5(2,3-dichlorophenoxy)-l ,2- phenylenediamine in step c is directly cyclized with carbon disulfide in presence of strong base such as caustic lye without isolating followed by acidification with acetic acid.
In yet another embodiment of the invention, Triclabendazole methanesulfonate salt is dissolved in an alcoholic solvent preferably methanol, charcolated and added concentrated hydrochloric acid and cooled to isolate hydrochloride salt of Triclabendazole. Which is further treated with water and ammonia to obtain Triclabendazole.
In yet another embodiment of the invention, 6-chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2 -thiol of formula II is methylated using a methylating agent like dimethylsulfate in presence of an alcoholic solvent preferably methanol and a base preferably sodium carbonate in temperature range of 40 to 90 °C preferably 60 to 90 °C. to obtain Triclabendazole directly.
In still further embodiment of the invention the obtained triclabendazole is optionally purified by dissolving in toluene at 90 -100 °C, removing water azeotropically, cooling & charcolyzing, and again adding isopropanol at 90 -100 °C.
The preferred embodiment of the invention can be illustrated by the below given examples, however it should not be construed to limit the scope of the invention.
Example 1: Preparation of 5-chIoro-6-(2,3-dichlorophenoxy)-2-(methylthio)-lH- benzimidazole (I)
(a) Preparation of 4-chloro-5(2,3-dichlorophenoxy)-2-nitroaniline;
2, 3-dichIorophenol (1 kg) in DMF (1.5 L), 2-nitro 4,5-dichloroacetanilide (1.52 kg), and potassium carbonate were heated into the flask for 12 hrs while maintaining the temperature at 90°C under vacuum and after that cooled to room temperature. Methanol (2 L), 48% caustic lye (0.3 kg) in 300 mL water were added to it and heated to 50°C for 4 hrs. Further water (4 L) was added, stirred, filtered and washed with water and with methanol.
Weight= 2 kg.
(b) Preparation of 4-chloro-5(2,3-dichlorophenoxy)-l,2-phenylenediamine;
Raney nickel (10.8 g) was added into a reaction mixture containing 4-chIoro- 5(2,3-dichlorophenoxy)-2-nitroaniline (900 g), methanol (3.4 L) at RT, caustic lye (2.72 g). Nitrogen was flushed into and charged with hydrogen. The reaction mixture was heated slowly to 100°C for 12 hrs, cooled to RT and filtered.
Weight: 819 g
(c) Preparation of 6-chloro-5(2,,3-dichlorophenoxy)-lH- benzimidazole-2- thiol:
In the mixture of 4-chloro-5(2,3-dichlorophenoxy)-l ,2-phenylenediamine in methanol (800 g) and caustic lye (245 mL), carbondisulfide (259 g) was added slowly and the reaction mass was refluxed' for 6 hrs. After completion of the reaction water (2.5 L) and acetic acid was added over a period of 2hrs at 60°C. Water was added (2.5 litre) again and heated to 90°C for 2hrs, filtered and washed with hot water to obtain the title compound.
Weight: 863 g.
(d) Preparation of 6-chloro-5(2.3-dichlorophenoxy)-2-(metylthio)-lH- benzimidazole:
6-chloro-5(2,3-dichlorophenoxy)-l H- benzimidazole-2-thiol(400kg) was added to methanol (700 L) and heated to 40°C. Dimethyl sulphate was added slowly at 40°C to it. The reaction mass was heated to 60-65°C and maintain for 6hrs. After completion of the reaction the reaction mass was cooled to 15°C, centrifuged the material and washed with 75 L of methanol to obtain wet cake of Triclabendazole methanesulfonate (520-560 kg).
Triclabendazole methanesulfonate (200 g) and methanol (1.2 L) was refluxed, cooled and charcoal was added and refluxed again for 1 hr. The reaction mass was filtered and concentrated hydrochloric acid was added. The precipitate was' cooled to RT, stirred for 1 hr, filtered and Triclabendazole hydrochloride was isolated (250 g wet) .
The water was added to the above Triclabendazole hydrochloride and ammonia was charged and stired for 2-3 hrs. The reaction mass was filtered, washed with water and dried to obtain Triclabendazole.
Weight: 156 g.
Example 2:Preparation of 6-chloro-5(2,3-dichlorophenoxy)-2-(metylthio)-lH- benzimidazole
In a RBF methanol (200 mL), 6-chloro-5(2,3-dichlorophenoxy)-lH- benzimidazole-2-thiol ((200 g) and dimethylsulfate (40 g) were heated to 60 ± 2°C and water (100 mL) was added and stirred for half an hr. Sodium carbonate solution (25 g Na2CC>3 in 200 mL water) was added slowly and temperature was raised to 60 °C and stirred for VA hr. After completion of reaction, the reaction mixture was cooled to 60°C, filtered, washed with water further washed with toluene and dried.
To the above wet crude 6-chloro-5(2,3-dichlorophenoxy)-2-(metylthio)-lH- benzimidazole, toluene (500 mL) was charged and water was removed azeotropically using Dean Stark apparatus. The mixture was heated to 100-1 12°C and 5 g charcoal was added, stirred for half an hr at 100-105°C. The reaction mixture was filtered through hyflow bed and washed with fresh toluene. The mother liquor was cooled to 70°C and isopropanol (7 mL) was added, cooled to room temperature to precipitate, filtered and washed with fresh toluene, dried at 75°C for 4 hrs to obtain pure Triclabendazole.
Yield of Triclabendazole is 85 gm. (81.7%).
Example 3: Purification of Triclabendazole:
The wet cake of Triclabendazole was heated to 90-100°C in toluene (1.92 litre). Water was removed azeotropically. The solution/mixture was cooled charcoal was added, refluxed and filtered. Again the obtained material was heated to 90-100°C, 180 ml of IPA was added, cooled to RT, filtered and dried for 24 hrs at 90-100°C.
Wt: 132 g (1st crop) and \2±\ g (2nd crop)
Claims
1. A process for the preparation of Triclabendazole comprising:
a) condensing N-(4,5-dichloro-2-nitrophenyl)acetamide with 2,3-dichlorophenol to obtain 4-chloro-5(2,3-dichlorophenoxy)-2-nitrophenyl acetamide;
b) hydrolysing 4-chloro-5(2,3-dichlorophenoxy)-2-nitrophenyl acetamide to obtain 4-chloro-5(2,3-dichlorophenoxy)-2-nitroaniline of;
c) reducing 4-chloro-5(2,3-dichlorophenoxy)-2-nitroaniline in presence of Raney nickel to obtain 4-chloro-5-(2,3-dichlorophenoxy)benzene-l ,2-diamine;
d) cyclising 4-chloro-5-(2,3-dichlorophenoxy)benzene-l ,2-diamine in presence of carbondisulfide to obtain 6-chloro-5-(2,3-dichlorophenoxy)-lH- benzimidazole-2-thiol; and
e) methylating 6-chloro-5 -(2,3 -dichlorophenoxy)- 1 H-benzim idazole-2 -thiol using a methylating agent to obtain Triclabendazole.
2. A process for the preparation of Triclabendazole according to claim 1, wherein the condensation and hydrolysis in step a) and b) is carried out in-situ in presence of solvent selected from dimethylformamide (DMF), DMSO, sulfolane, N- methylpyrrolidinone and methanol at a temperature 30 °C to 100°C.
3. A process for the preparation of Triclabendazole according to claim 1, wherein the condensation and hydrolysis in step a) and b) is carried out in-situ in presence of a base sodium carbonate, potassium carbonate, or sodium hydroxide or potassium hydroxide.
4. A process for the preparation of Triclabendazole according to claim 1, wherein the condensation in step a) is carried out in absence of a phase transfer catalyst.
5. A process for the preparation of Triclabendazole according to claim 1, wherein the reduction in step c) is carried out in presence of an alcoholic solvent like methanol and a base sodium hydroxide.
6. A process for the preparation of Triclabendazole according to claim 1, wherein cyclisation in step d) is carried out in a solvent selected from dimethylformamide, methanol, ethanol, acetonitrile or mixture thereof and a base like sodium hydroxide.
7. A process for the preparation of Triciabendazole according to claim 1, where in methylation of 6-chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2-thiol to obtain Triciabendazole comprises:
a) methylating 6-chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2-thiol using a methylating agent to obtain Triciabendazole methanesulfonate salt; b) converting Triciabendazole methanesulfonate salt to a hydrochloride salt of Triciabendazole; and
c) hydrolysing Triciabendazole hydrochloride to obtain Triciabendazole.
8. A process for the preparation of Triciabendazole according to claim 1 , where in 6- chloro-5-(2,3-dichlorophenoxy)-lH-benzimidazole-2-thiol is methylated using a methylating agent in presence of an alcoholic solvent like methanol and a base like sodium carbonate, potassium carbonate in temperature range of 40 to 90 °C to obtain Triciabendazole directly.
9. A process for the preparation of Triciabendazole according to any of the previous claim, wherein the methylating agent used is dimethylsulfate.
10. A process for the preparation of Triciabendazole according to claim 1, wherein the obtained Triciabendazole is crystallised using toluene and isopropanol.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11843342.4A EP2642995A2 (en) | 2010-11-24 | 2011-11-23 | Process for preparation of triclabendazole |
| US13/989,147 US20130303781A1 (en) | 2010-11-24 | 2011-11-23 | Process for preparation of triclabendazole |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3538CH2010 | 2010-11-24 | ||
| IN3538/CHE/2010 | 2010-11-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012070068A2 true WO2012070068A2 (en) | 2012-05-31 |
| WO2012070068A3 WO2012070068A3 (en) | 2012-07-19 |
Family
ID=46146225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2011/000810 WO2012070068A2 (en) | 2010-11-24 | 2011-11-23 | Process for preparation of triclabendazole |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20130303781A1 (en) |
| EP (1) | EP2642995A2 (en) |
| WO (1) | WO2012070068A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103319417A (en) * | 2013-06-24 | 2013-09-25 | 常州佳灵药业有限公司 | Method for preparing triclabendazole sulfoxide |
| CN103319416A (en) * | 2013-06-24 | 2013-09-25 | 常州佳灵药业有限公司 | Novel veterinary drug triclabendazole sulfoxide and preparation method thereof |
| CN103360323A (en) * | 2013-06-24 | 2013-10-23 | 常州佳灵药业有限公司 | Preparation method of triclabendazole |
| CN104230815A (en) * | 2013-06-07 | 2014-12-24 | 连云港市亚晖医药化工有限公司 | Preparation method of triclabendazole |
| US11053203B2 (en) | 2017-11-13 | 2021-07-06 | Ecolab Usa Inc. | One-pot homogeneous process for the large scale manufacture of 2-substituted benzimidazoles |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218375A (en) * | 2015-10-31 | 2016-01-06 | 丁玉琴 | A kind of synthetic method of 2-methyl-4-nitrobenzoic acid |
| CN109053585B (en) * | 2018-09-13 | 2020-10-23 | 暨明医药科技（苏州）有限公司 | Synthetic method of triclabendazole |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2529887A (en) * | 1949-05-19 | 1950-11-14 | Du Pont | Process for the preparation of anisole |
| US3538108A (en) * | 1967-08-17 | 1970-11-03 | Merck & Co Inc | Water - soluble 2 - substituted benzimidazole methanesulfonic acid salts |
| US4197307A (en) * | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4492708A (en) * | 1982-09-27 | 1985-01-08 | Eli Lilly And Company | Antiviral benzimidazoles |
| CN101555231B (en) * | 2009-05-04 | 2011-03-23 | 扬州天和药业有限公司 | Method for preparing triclabendazole |
-
2011
- 2011-11-23 WO PCT/IN2011/000810 patent/WO2012070068A2/en active Application Filing
- 2011-11-23 US US13/989,147 patent/US20130303781A1/en not_active Abandoned
- 2011-11-23 EP EP11843342.4A patent/EP2642995A2/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2529887A (en) * | 1949-05-19 | 1950-11-14 | Du Pont | Process for the preparation of anisole |
| US3538108A (en) * | 1967-08-17 | 1970-11-03 | Merck & Co Inc | Water - soluble 2 - substituted benzimidazole methanesulfonic acid salts |
| US4197307A (en) * | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
Non-Patent Citations (4)
| Title |
|---|
| HERNANDEZ-LUIS ET AL.: 'Synthesis and biological activity of 2-trifluoromethyl)-1 H-benzimidazole derivatives against some protozoa and Trichinella spiralis' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY vol. 45, 07 April 2010, pages 3135 - 3141, XP027050440 * |
| SORIA-ARTECHE ET AL.: 'Studies on the Selective S-oxidation of Albendazole, Fenbendazole, Triclabendazole, and Other Benzimidazole Sulfides' J.MED.CHEM.SOC. vol. 49, no. 4, 2005, pages 353 - 358, XP055116213 * |
| TOWNSEND ET AL.: 'The Synthesis and Chemistry of Certain Anthelmintic Benzimidazoles' PARASITOLOGY TODAY vol. 6, no. 4, 1990, pages 107 - 112, XP055116216 * |
| ZHOU ET AL.: 'Separation and characterization of synthetic impurites of triclabendazole by reversed -phase high performance liquid chromatography/electrospray ionization mass spectrometry' JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS vol. 37, 2005, pages 97 - 107, XP027718678 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104230815A (en) * | 2013-06-07 | 2014-12-24 | 连云港市亚晖医药化工有限公司 | Preparation method of triclabendazole |
| CN103319417A (en) * | 2013-06-24 | 2013-09-25 | 常州佳灵药业有限公司 | Method for preparing triclabendazole sulfoxide |
| CN103319416A (en) * | 2013-06-24 | 2013-09-25 | 常州佳灵药业有限公司 | Novel veterinary drug triclabendazole sulfoxide and preparation method thereof |
| CN103360323A (en) * | 2013-06-24 | 2013-10-23 | 常州佳灵药业有限公司 | Preparation method of triclabendazole |
| CN103319417B (en) * | 2013-06-24 | 2014-07-09 | 常州佳灵药业有限公司 | Method for preparing triclabendazole sulfoxide |
| CN103360323B (en) * | 2013-06-24 | 2014-07-09 | 常州佳灵药业有限公司 | Preparation method of triclabendazole |
| CN103319416B (en) * | 2013-06-24 | 2015-02-25 | 常州佳灵药业有限公司 | Novel veterinary drug triclabendazole sulfoxide and preparation method thereof |
| US11053203B2 (en) | 2017-11-13 | 2021-07-06 | Ecolab Usa Inc. | One-pot homogeneous process for the large scale manufacture of 2-substituted benzimidazoles |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2642995A2 (en) | 2013-10-02 |
| US20130303781A1 (en) | 2013-11-14 |
| WO2012070068A3 (en) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012070068A2 (en) | Process for preparation of triclabendazole | |
| US7943781B2 (en) | Process for preparing telmisartan | |
| ES2369081T3 (en) | PROCEDURE FOR THE PREPARATION OF TELMISARTAN. | |
| WO2012028925A2 (en) | An improved process for the preparation of telmisartan | |
| WO2012070069A2 (en) | A process for preparation of albendazole | |
| DK169965B1 (en) | Process for Preparation of 4-Substituted Indolin-2-Ones and Intermediates for Use | |
| US20210139493A1 (en) | Preparation of velpatasvir and derivative thereof | |
| TWI291959B (en) | Process for preparing granisetron | |
| AU703431B2 (en) | Benzimidazole derivatives having dopaminergic activity | |
| US20130317234A1 (en) | Process for Preparation of Intermediates of Bendamustine | |
| CA1076582A (en) | Antiviral thiazolinyl or thiazinyl ketobenzimidazoles | |
| US4018790A (en) | Substituted 1-sulfonylbenzimidazoles | |
| US20160214987A1 (en) | Method for preparing an intermediate for producing high-purity pemetrexed and method for producing high-purity pemetrexed using the intermediate | |
| JP2008531642A (en) | Method for obtaining pharmaceutically active compound irbesartan and synthetic intermediates thereof | |
| CA2693513A1 (en) | An improved process for the preparation of candesartan cilexetil | |
| CN111333535B (en) | Preparation method of trifloxystrobin | |
| US7141667B2 (en) | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one | |
| WO2009116089A2 (en) | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. | |
| Horning et al. | Synthesis of phenols from diazonium tetrafluoroborates; a useful modification | |
| EP1918288A1 (en) | A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension | |
| US8106216B2 (en) | Process for the preparation of Irbesartan | |
| WO2010149565A1 (en) | Process for preparing telmisartan | |
| US7547791B2 (en) | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | |
| US4196125A (en) | Substituted 1-sulfonylbenzimidazoles | |
| US4243813A (en) | Substituted 1-sulfonylbenzimidazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11843342 Country of ref document: EP Kind code of ref document: A2 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011843342 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13989147 Country of ref document: US |